Breaking Finance News

Zacks Investment Research downgraded Audentes Therapeutics Inc (NASDAQ:BOLD) to Sell in a report released today.

Zacks Investment Research has downgraded Audentes Therapeutics Inc (NASDAQ:BOLD) to Sell in a report released on 10/12/2016.

Just yesterday Audentes Therapeutics Inc (NASDAQ:BOLD) traded 1.53% higher at $19.25. Audentes Therapeutics Inc’s 50-day moving average is $15.91 and its 200-day moving average is $15.51. The last stock price is up 24.13% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 40,055 shares of BOLD traded hands, down from an average trading volume of 120,359

Recent Performance Chart

Audentes Therapeutics Inc (NASDAQ:BOLD)

Audentes Therapeutics Inc has 52 week low of $13.06 and a 52 week high of $20.42 and has a market capitalization of $0.

Brief Synopsis On Audentes Therapeutics Inc (NASDAQ:BOLD)

Audentes Therapeutics, Inc. is a biotechnology company. The Company focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. Its portfolio of product candidates include AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). AT132 is an Adeno-associated virus (AAV) 8 vector containing a functional copy of the MTM1 gene. The Company is engaged in developing AT342, which is an AAV8 vector, containing a functional version of the UGT1A1 gene. The AT982 uses an AAV serotype 9 capsid vector, containing a functional copy of the glucosidase alpha, acid (GAA) gene. The Company's principal operations are located in San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.